220 related articles for article (PubMed ID: 1730031)
41. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
42. Adsorption to fibrin of native fragments of known primary structure from human plasminogen.
Thorsen S; Clemmensen I; Sottrup-Jensen L; Magnusson S
Biochim Biophys Acta; 1981 May; 668(3):377-87. PubMed ID: 7236714
[TBL] [Abstract][Full Text] [Related]
43. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
44. Release of B beta peptides from fibrinogen or fibrin in the presence of alpha 2 antiplasmin.
Takada A; Makino Y; Takada Y
Thromb Res; 1986 Apr; 42(1):1-9. PubMed ID: 2422782
[TBL] [Abstract][Full Text] [Related]
45. Mechanism of action of omega-amino acids on plasminogen activation and fibrinolysis induced by staphylokinase.
Levashov MY; Aisina RB; Gershkovich KB; Varfolomeyev SD
Biochemistry (Mosc); 2007 Jul; 72(7):707-15. PubMed ID: 17680762
[TBL] [Abstract][Full Text] [Related]
46. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
47. Involvement of protease inhibitors in staphylokinase-induced fibrin-specific fibrinolysis.
Shishido Y; Sakai M; Kaneda N; Sansawa H; Shimura K; Hashimoto S; Yokokura T
Biol Pharm Bull; 1994 Dec; 17(12):1595-8. PubMed ID: 7735201
[TBL] [Abstract][Full Text] [Related]
48. Kinetic analysis of plasminogen activation by staphylokinase/plasminogen complex in the presence of fibrin.
Okada K; Yuasa H; Hagiya Y; Fukao H; Ueshima S; Matsuo O
Thromb Res; 1994 Oct; 76(2):181-91. PubMed ID: 7863467
[TBL] [Abstract][Full Text] [Related]
49. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
50. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
[TBL] [Abstract][Full Text] [Related]
51. Role of the kringle domain in plasminogen activation with staphylokinase.
Arai K; Madoiwa S; Mimuro J; Asakura S; Matsuda M; Sako T; Sakata Y
J Biochem; 1998 Jan; 123(1):71-7. PubMed ID: 9504411
[TBL] [Abstract][Full Text] [Related]
52. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?
Collen D; Lijnen HR
Blood; 1994 Aug; 84(3):680-6. PubMed ID: 7519069
[No Abstract] [Full Text] [Related]
53. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen.
Grailhe P; Nieuwenhuizen W; Anglés-Cano E
Eur J Biochem; 1994 Feb; 219(3):961-7. PubMed ID: 8112348
[TBL] [Abstract][Full Text] [Related]
54. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
Cassels R; Fears R; Smith RA
Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
[TBL] [Abstract][Full Text] [Related]
55. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
[TBL] [Abstract][Full Text] [Related]
56. Functional properties of p-anisoylated plasmin-staphylokinase complex.
Lijnen HR; Van Hoef B; Smith RA; Collen D
Thromb Haemost; 1993 Aug; 70(2):326-31. PubMed ID: 8236143
[TBL] [Abstract][Full Text] [Related]
57. Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator.
Wojta J; Beckmann R; Turcu L; Wagner OF; van Zonneveld AJ; Binder BR
J Biol Chem; 1989 May; 264(14):7957-61. PubMed ID: 2470738
[TBL] [Abstract][Full Text] [Related]
58. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes.
Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B
Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258
[TBL] [Abstract][Full Text] [Related]
59. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
Singh S; Houng A; Reed GL
Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
[TBL] [Abstract][Full Text] [Related]
60. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy.
Mohler MA; Refino CJ; Chen SA; Chen AB; Hotchkiss AJ
Thromb Haemost; 1986 Oct; 56(2):160-4. PubMed ID: 2433785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
